How can an ESBL‑producing Escherichia coli infection present as a urinary tract infection in a 62‑year‑old patient?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 5, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

How ESBL-Producing E. coli Presents as UTI in a 62-Year-Old

In a 62-year-old patient, ESBL-producing E. coli UTI can present with either typical urinary symptoms (dysuria, frequency, urgency, suprapubic pain) or atypical manifestations including altered mental status, functional decline, fatigue, or falls—particularly if the patient has comorbidities or frailty. 1

Clinical Presentation Patterns

Typical Urinary Symptoms

The infection may present with classic UTI features including:

  • Recent onset dysuria (key diagnostic criterion)
  • Urinary frequency, urgency, or new/worsening incontinence
  • Suprapubic pain or discomfort
  • Costovertebral angle tenderness (suggesting pyelonephritis)
  • Fever (>37.8°C oral, or >37.5°C rectal) 1

Atypical Presentations (Common in Older Adults)

Older patients frequently present without classic urinary symptoms, instead showing 1:

  • Altered mental status (new confusion or delirium)
  • Functional decline (decreased mobility, ADL impairment)
  • Falls or dizziness
  • Fatigue or generalized weakness
  • Decreased oral intake or nausea

Severe Manifestations

The case report 2 of a 62-year-old man with ESBL E. coli demonstrates that presentation can include:

  • Nausea and altered mental status
  • Multiple renal abscesses on imaging
  • Bacteremia (positive blood cultures)
  • Systemic inflammatory response with elevated CRP 3

Key Diagnostic Considerations

Risk Factors Present in This Age Group

ESBL-producing organisms should be suspected when 4:

  • Male gender (OR 2.72) 3
  • History of recurrent UTI (OR 3.14) 3
  • Recent hospitalization (within 3 months) 5
  • Prior antibiotic exposure (within 3 months) 6, 5
  • Urological procedures or instrumentation 7
  • Presence of urinary catheter 7
  • Multiple comorbidities (≥2 conditions) 6

Diagnostic Algorithm for 62-Year-Olds

Start with symptom assessment 1:

  1. If recent onset dysuria PLUS systemic signs (fever >37.8°C, rigors, clear delirium):

    • Prescribe antibiotics (unless dipstick negative for both nitrite AND leukocyte esterase)
  2. If frequency/urgency/incontinence OR costovertebral tenderness:

    • Prescribe antibiotics
  3. If only nonspecific symptoms (cloudy urine, fatigue, decreased intake, mental status change without clear delirium):

    • Do NOT automatically treat as UTI
    • Evaluate for other causes and actively monitor

Critical Pitfall to Avoid

Do not confuse asymptomatic bacteriuria with infection 1. The specificity of urine dipstick tests is only 20-70% in older adults 1. Mere detection of bacteria does not confirm UTI—symptoms must be present.

Classification as Complicated UTI

ESBL-producing organisms automatically classify this as a complicated UTI 4. The 2024 EAU guidelines explicitly list "ESBL-producing organisms isolated" as a complicating factor requiring different management than uncomplicated UTI.

Additional factors making this complicated in a 62-year-old:

  • Male gender (all UTIs in males are considered complicated) 4
  • Potential for anatomic/functional urinary tract abnormalities
  • Higher likelihood of multidrug resistance 4

Severity Assessment

Evaluate for secondary bacteremia, which occurs more frequently with ESBL infections (OR 4.95) 3. The patient in the case report 2 had positive blood cultures requiring both antimicrobial therapy and surgical intervention (nephrectomy).

Higher CRP values at diagnosis are significantly associated with ESBL-producing infections (p=0.004) 3, suggesting more severe inflammatory response.

Management Implications

Obtain urine culture and susceptibility testing before initiating therapy 4. Given the high resistance rates in ESBL strains:

  • Complete resistance to cephalosporins expected
  • High co-resistance to fluoroquinolones common 8, 9
  • Carbapenems may be prioritized empirically in patients with known ESBL risk factors 3
  • Fosfomycin shows lowest resistance rates (4.9%) for oral options 5

Treatment duration: 7-14 days depending on severity and whether prostatitis can be excluded (14 days for men when prostatitis cannot be ruled out) 4.

References

Research

Carbon dioxide-dependent, extended-spectrum β-lactamase producing Escherichia coli bacteremia associated with pyelonephritis: A case-report.

Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy, 2025

Related Questions

What is the correct sterile technique for self‑intermittent catheterization in a patient with a prior ESBL‑producing E. coli urinary infection?
What is the appropriate treatment for an ESBL-producing urinary tract infection?
What is the safest oral empiric antibiotic for a non‑pregnant adult with a urinary tract infection and a history of ESBL‑producing Escherichia coli?
If my urinalysis is normal and I am colonized with extended‑spectrum β‑lactamase (ESBL)‑producing Escherichia coli, should my urine culture be sterile?
What is the appropriate evaluation and treatment for a patient with markedly positive leukocyte esterase, mild pyuria, negative nitrites, difficulty urinating, and a history of ESBL‑producing Escherichia coli infection?
How does one differentiate spondylodiscitis from a subacute compression (impression) fracture of a lumbar vertebral body on MRI?
What is the recommended duration of streptomycin therapy in the treatment of tuberculous meningitis?
In a patient with chronic liver disease and portal hypertension who has bleeding from a liver biopsy site, would tranexamic acid be effective in controlling the bleed?
In a patient with chronic liver disease and portal hypertension who has a percutaneous liver‑biopsy site bleed, how do the colour, appearance, and volume of the bleeding influence management?
What is the appropriate prednisolone dosage and duration for severe acute alcoholic hepatitis without contraindications such as active infection, uncontrolled diabetes, or gastrointestinal bleeding?
What is the appropriate eight‑week prednisolone taper regimen for a patient with alcoholic hepatitis who has a Lille score <0.45 at day 7?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.